CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

@article{Picard2011CYP3A5GD,
  title={CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.},
  author={Nicolas Picard and Koukeb Rouguieg-Malki and Nassim Kamar and Lionel P E Rostaing and Pierre Marquet},
  journal={Transplantation},
  year={2011},
  volume={91 6},
  pages={652-6}
}
BACKGROUND CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the… CONTINUE READING